This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
APICA: Difference between revisions
>Tracer m Grammatics |
>LockPicker m Revised german legal status, merged redundant references |
||
| Line 2: | Line 2: | ||
{{SubstanceBox/APICA}} | {{SubstanceBox/APICA}} | ||
'''APICA''' (also known as '''SDB-001''', and '''2NE1''') is a novel synthetic [[psychoactive class::cannabinoid]] that produces modified [[cannabis|cannabis-like]] effects when [[routes of administration|administered]]. It has been shown to act as a potent [[agonist]] for the CB1 and CB2 [[cannabinoid]] [[receptors]].<ref>Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience. 2015;6(8);1445-1458;doi:10.1021/acschemneuro.5b00107 (Pubmed / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25921407</ref> | '''APICA''' (also known as '''SDB-001''', and '''2NE1''') is a novel synthetic [[psychoactive class::cannabinoid]] that produces modified [[cannabis|cannabis-like]] effects when [[routes of administration|administered]]. It has been shown to act as a potent [[agonist]] for the CB1 and CB2 [[cannabinoid]] [[receptors]].<ref name="Banister2015">Samuel D. Banister, Jordyn Stuart, Richard C. Kevin, Amelia Edington, Mitchell Longworth, Shane M. Wilkinson, Corinne Beinat, Alexandra S. Buchanan, David E. Hibbs, Michelle Glass, Mark Connor, Iain S. McGregor, and Michael Kassiou. "Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135" Chemical Neuroscience. 2015;6(8);1445-1458;doi:10.1021/acschemneuro.5b00107 (Pubmed / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25921407</ref> | ||
The name "2NE1" appears to be a reference to the South Korean all-girl K-Pop group,<ref>2NE1 (Wikipedia) | https://en.wikipedia.org/wiki/2NE1</ref> a naming convention shared by the closely related chemical [[AKB48]]. In 2011, the two chemicals were first identified in Japan as a mixture in a product sold under the name "Fragrance Powder".<ref>Nahoko Uchiyama, Maiko Kawamura, Ruri Kikura-Hanajiri, Yukihiro Goda. "Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide(APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products" Forensic Toxicology (2012) 30: 114-125. https://doi.org/10.1007/s11419-012-0136-7</ref> APICA has since been available for sale as a grey-area [[research chemical]] through online vendors. | The name "2NE1" appears to be a reference to the South Korean all-girl K-Pop group,<ref>2NE1 (Wikipedia) | https://en.wikipedia.org/wiki/2NE1</ref> a naming convention shared by the closely related chemical [[AKB48]]. In 2011, the two chemicals were first identified in Japan as a mixture in a product sold under the name "Fragrance Powder".<ref>Nahoko Uchiyama, Maiko Kawamura, Ruri Kikura-Hanajiri, Yukihiro Goda. "Identification of two new-type synthetic cannabinoids, N-(1-adamantyl)-1-pentyl-1H-indole-3-carboxamide (APICA) and N-(1-adamantyl)-1-pentyl-1H-indazole-3-carboxamide(APINACA), and detection of five synthetic cannabinoids, AM-1220, AM-2233, AM-1241, CB-13 (CRA-13), and AM-1248, as designer drugs in illegal products" Forensic Toxicology (2012) 30: 114-125. https://doi.org/10.1007/s11419-012-0136-7</ref> APICA has since been available for sale as a grey-area [[research chemical]] through online vendors. | ||
| Line 18: | Line 18: | ||
APICA acts as a full agonist of the cannabinoid [[receptors]], with similar potency at both [[CB1]] and [[CB2]]. In vivo experiments measuring the response of rats to APICA and similar drugs found that APICA had a similar potency to Δ9-[[THC]] and around a third the potency of [[JWH-018]]. In comparison to these other cannabinoids, APICA appeared to elicit a longer duration of effect. Caution should be exercised in interpreting studies using animals, however, as effects may differ significantly in humans.<ref>Banister SD, Wilkinson SM, Longworth M, et al. The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience. 2013;4(7):1081-1092. doi:10.1021/cn400035r. (PMC/NCBI) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715837/</ref> | APICA acts as a full agonist of the cannabinoid [[receptors]], with similar potency at both [[CB1]] and [[CB2]]. In vivo experiments measuring the response of rats to APICA and similar drugs found that APICA had a similar potency to Δ9-[[THC]] and around a third the potency of [[JWH-018]]. In comparison to these other cannabinoids, APICA appeared to elicit a longer duration of effect. Caution should be exercised in interpreting studies using animals, however, as effects may differ significantly in humans.<ref>Banister SD, Wilkinson SM, Longworth M, et al. The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience. 2013;4(7):1081-1092. doi:10.1021/cn400035r. (PMC/NCBI) | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3715837/</ref> | ||
Pharmacological studies have reported EC<sub>50</sub> values of 6.89 ± 0.11nM at CB1 and 7.54 ± 0.11nM at CB2.<ref | Pharmacological studies have reported EC<sub>50</sub> values of 6.89 ± 0.11nM at CB1 and 7.54 ± 0.11nM at CB2.<ref name="Banister2015"></ref> It is likely that APICA shares many of the in vivo properties of [[Δ9-THC]]. However, the role of these interactions and how they result in the cannabinoid high has yet to be scientifically validated. | ||
In vivo metabolic studies on APICA have shown that the drug is fully metabolized with none of the original compound detectable in urine. The major metabolites were mono- or dihydroxylated on the adamantyl ring system and monohydroxylated on the pentyl chain.<ref>Tim Sobolevsky, Ilya Prasolov and Grigory Rodchenkov. "Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue". Drug Testing and Analysis. 2015;7(2);131-142;doi:10.1002/dta.1756 (Pubmed / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25428705</ref> | In vivo metabolic studies on APICA have shown that the drug is fully metabolized with none of the original compound detectable in urine. The major metabolites were mono- or dihydroxylated on the adamantyl ring system and monohydroxylated on the pentyl chain.<ref>Tim Sobolevsky, Ilya Prasolov and Grigory Rodchenkov. "Study on the phase I metabolism of novel synthetic cannabinoids, APICA and its fluorinated analogue". Drug Testing and Analysis. 2015;7(2);131-142;doi:10.1002/dta.1756 (Pubmed / NCBI) | https://www.ncbi.nlm.nih.gov/pubmed/25428705</ref> | ||
| Line 29: | Line 29: | ||
*'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of APICA can be described as a sharp, uncomfortable, all-encompassing, and electric tingling sensation that spreads over the body after initial ingestion. It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached before immediately dissipating. | *'''[[Effect::Spontaneous physical sensations]]''' - The "body high" of APICA can be described as a sharp, uncomfortable, all-encompassing, and electric tingling sensation that spreads over the body after initial ingestion. It maintains a consistent presence that quickly rises with the onset and hits its limit once the peak has been reached before immediately dissipating. | ||
*'''[[Effect::Motor control loss]]''' - This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose, but rarely results in a complete inability to walk and perform basic movements. | *'''[[Effect::Motor control loss]]''' - This substance causes a partial to moderate suppression of motor control which intensifies proportional to dose, but rarely results in a complete inability to walk and perform basic movements. | ||
*'''[[Effect::Appetite enhancement]]''' - As with many other cannabinoids, APICA causes an increase in appetite<ref>Mechoulam, R. (1984). Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press. ISBN 0-8493-5772-1.</ref>, known colloquially as "the munchies" in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food.<ref>How Marijuana Works | http://science.howstuffworks.com/marijuana4.htm</ref> This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.<ref> | *'''[[Effect::Appetite enhancement]]''' - As with many other cannabinoids, APICA causes an increase in appetite<ref>Mechoulam, R. (1984). Cannabinoids as therapeutic agents. Boca Raton, FL: CRC Press. ISBN 0-8493-5772-1.</ref>, known colloquially as "the munchies" in popular American and United Kingdom culture. Clinical studies and survey data have found that cannabis increases food enjoyment and interest in food.<ref name="HMW">How Marijuana Works | http://science.howstuffworks.com/marijuana4.htm</ref> This is thought to be due to the way in which endocannabinoids in the hypothalamus activate cannabinoid receptors that are responsible for maintaining food intake.<ref name="HMW"></ref> | ||
*'''[[Effect::Pain relief]]''' - Cannabinoids have been clinically demonstrated to provide pain relief via agonism of cannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub>, which extends to [[synthetic cannabinoid]] receptor agonists.<ref>http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2009.00703.x/abstract</ref><ref>Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2011.03970.x/abstract</ref> | *'''[[Effect::Pain relief]]''' - Cannabinoids have been clinically demonstrated to provide pain relief via agonism of cannabinoid receptors CB<sub>1</sub> and CB<sub>2</sub>, which extends to [[synthetic cannabinoid]] receptor agonists.<ref>http://onlinelibrary.wiley.com/doi/10.1111/j.1526-4637.2009.00703.x/abstract</ref><ref>Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials | http://onlinelibrary.wiley.com/doi/10.1111/j.1365-2125.2011.03970.x/abstract</ref> | ||
*'''[[Effect::Perception of bodily heaviness]]''' or '''[[Perception of bodily lightness]]''' | *'''[[Effect::Perception of bodily heaviness]]''' or '''[[Perception of bodily lightness]]''' | ||
| Line 48: | Line 48: | ||
*'''[[Effect::analysis suppression]]''' | *'''[[Effect::analysis suppression]]''' | ||
*'''[[Effect::Dream suppression]]''' | *'''[[Effect::Dream suppression]]''' | ||
*'''[[Effect::Psychosis]]''' - The prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to psychosis,<ref>Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref> particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref>Every-Palmer, S. [[Synthetic cannabinoid]] use and psychosis: an explorative study. Journal of Drug and Alcohol Dependence 2011.</ref><ref>“Spice” Girls: Synthetic Cannabinoid Intoxication - The Journal of Emergency Medicine Volume 40, Issue 3, March 2011, Pages 296–299 (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0736467910008802</ref><ref>A Teenager With Agitation: Higher Than She Should Have Climbed - Pediatric Emergency Care: June 2010 - Volume 26 - Issue 6 - pp 462-465 | http://journals.lww.com/pec-online/Abstract/2010/06000/A_Teenager_With_Agitation__Higher_Than_She_Should.16.aspx</ref> | *'''[[Effect::Psychosis]]''' - The prolonged usage of synthetic [[cannabinoids]] may increase one's disposition to psychosis,<ref>Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref> particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref name="Every-Palmer2011">Every-Palmer, S. [[Synthetic cannabinoid]] use and psychosis: an explorative study. Journal of Drug and Alcohol Dependence 2011.</ref><ref name="Schneir2011">“Spice” Girls: Synthetic Cannabinoid Intoxication - The Journal of Emergency Medicine Volume 40, Issue 3, March 2011, Pages 296–299 (ScienceDirect) | http://www.sciencedirect.com/science/article/pii/S0736467910008802</ref><ref name="Vearrier2010">A Teenager With Agitation: Higher Than She Should Have Climbed - Pediatric Emergency Care: June 2010 - Volume 26 - Issue 6 - pp 462-465 | http://journals.lww.com/pec-online/Abstract/2010/06000/A_Teenager_With_Agitation__Higher_Than_She_Should.16.aspx</ref> | ||
}} | }} | ||
| Line 66: | Line 66: | ||
The toxicity and long-term health effects of recreational APICA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because APICA has very little history of human usage. Anecdotal evidence from people who have tried APICA within the community suggests that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). | The toxicity and long-term health effects of recreational APICA use do not seem to have been studied in any scientific context and the [[Toxicity::exact toxic dosage is unknown]]. This is because APICA has very little history of human usage. Anecdotal evidence from people who have tried APICA within the community suggests that there do not seem to be any negative health effects attributed to simply trying this substance at low to moderate doses by itself and using it sparingly (but nothing can be completely guaranteed). | ||
It is advised that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly amplify [[emotion enhancement|one's current state of mind and emotions]]. Also, as with [[THC]] and [[cannabis]], prolonged usage of synthetic [[cannabinoids]] including APICA may increase one's disposition to mental illness and psychosis,<ref>Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref> particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref | It is advised that those with severe pre-existing mental conditions should not ingest these substances due to the way they strongly amplify [[emotion enhancement|one's current state of mind and emotions]]. Also, as with [[THC]] and [[cannabis]], prolonged usage of synthetic [[cannabinoids]] including APICA may increase one's disposition to mental illness and psychosis,<ref>Causal association between cannabis and psychosis: examination of the evidence - The British Journal of Psychiatry Jan 2004, 184 (2) 110-117 | http://bjp.rcpsych.org/content/184/2/110.short</ref> particularly in vulnerable individuals with risk factors for psychotic illnesses (like a past or family history of schizophrenia).<ref name="Every-Palmer2011"></ref><ref name="Schneir2011"></ref><ref name="Vearrier2010"></ref> | ||
As synthetic cannabinoids are active in the milligram range (with below 5mg being a common dose), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience and injury to oneself or others. | As synthetic cannabinoids are active in the milligram range (with below 5mg being a common dose), it is important to [[Dosage|use proper precautions when dosing]] to avoid a negative experience and injury to oneself or others. | ||
| Line 82: | Line 82: | ||
==Legality== | ==Legality== | ||
{{legalStub}} | {{legalStub}} | ||
*'''China | *'''China''': As of October 2015 APICA is a controlled substance in China.<ref>关于印发《非药用类麻醉药品和精神药品列管办法》的通知 | http://www.sfda.gov.cn/WS01/CL0056/130753.html</ref> | ||
*'''Germany | *'''Germany''': APICA is controlled under Anlage II BtMG (''Narcotics Act, Schedule II'')<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/anlage_ii.html|title=Anlage II BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 30, 2019|language=de}}</ref> as of December 13, 2014.<ref>{{cite web|url=http://www.bgbl.de/xaver/bgbl/start.xav?startbk=Bundesanzeiger_BGBl&jumpTo=bgbl114s1999.pdf|title=Achtundzwanzigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften|publisher=Bundesanzeiger Verlag|work=Bundesgesetzblatt Jahrgang 2014 Teil I Nr. 57|publication-date=December 12, 2014|pages=1999-2002|access-date=December 19, 2019|language=de}}</ref> It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.<ref>{{cite web|url=https://www.gesetze-im-internet.de/btmg_1981/__29.html|title=§ 29 BtMG|publisher=Bundesministerium der Justiz und für Verbraucherschutz|access-date=December 19, 2019|language=de}}</ref> | ||
*'''United Kingdom | *'''United Kingdom''': APICA is a Class B controlled substance under the third-generation synthetic cannabinoids generic definition, which came into effect on the December 14, 2016 and is illegal to possess, produce, supply, or import. <ref>The Misuse of Drugs Act 1971 (Amendment) Order 2016 (Legislation.gov.uk) | http://www.legislation.gov.uk/uksi/2016/1109/made</ref> | ||
==See also== | ==See also== | ||